Fulgent Genetics Inc (NASDAQ:FLGT) has received a consensus broker rating score of 3.00 (Hold) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating. Fulgent Genetics’ rating score has declined by 50% from three months ago as a result of a number of analysts’ ratings changes.
Brokerages have set a 12 month consensus price objective of $4.35 for the company and are expecting that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also assigned Fulgent Genetics an industry rank of 187 out of 265 based on the ratings given to its competitors.
A number of research analysts have recently issued reports on the company. Credit Suisse Group lowered their price target on Fulgent Genetics from $6.50 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, March 1st. Piper Jaffray Companies downgraded Fulgent Genetics from an “overweight” rating to a “neutral” rating in a report on Thursday, March 1st. Finally, Zacks Investment Research raised Fulgent Genetics from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 9th.
Shares of Fulgent Genetics (NASDAQ:FLGT) traded up $0.03 during trading hours on Wednesday, hitting $3.85. The stock had a trading volume of 1,987 shares, compared to its average volume of 13,188. The company has a market capitalization of $68.53 and a P/E ratio of -25.67. Fulgent Genetics has a 1 year low of $2.72 and a 1 year high of $11.80.
COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/03/14/analysts-set-4-35-target-price-for-fulgent-genetics-inc-flgt.html.
About Fulgent Genetics
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.